Share Options Awarded
Bioventix plc announced on April 20, 2026, the award of share options under its 2020 Share Option Plan to its CEO, Peter Harrison, for 32,811 options at an exercise price of £17.75, bringing his total to 52,622, and to its CFO, Bruce Hiscock, for 9,967 options at the same exercise price, bringing his total to 14,394. These options vest between three and ten years and become exercisable upon the company achieving over £1.0 million in revenue from a commercial diagnostic partner for its neurological blood test.
Select text to share a quote on X · sign in to keep highlights & notes in your BVXP notes
Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces the award on 17 April 2026 of share options over ordinary shares in the Company (the "Options") under the Company's Share Option Plan in 2020 to the following directors, as follows:
| Director | Position | Number of Options | Exercise Price | Total Number of Options held following this award |
|---|---|---|---|---|
| Peter Harrison | CEO | 32,811 | £17.75 | 52,622 |
| Bruce Hiscock | CFO | 9,967 | £17.75 | 14,394 |
The Options vest between 3 and 10 years from grant and will become exercisable once the Company recognises revenue of greater than £1.0 million, as evidenced by audited financial statements prepared in accordance with UK GAAP, from a commercial diagnostic partner relating to its neurological blood test using the Company's sheep monoclonal antibody. The Options are subject to clawback and malus provisions.
| a) | Name | a) Peter Harrison b) Bruce Hiscock | |
| 2 | Reason for the notification | ||
| a) | Position/status | a) CEO b) CFO | |
| b) | Initial notification /Amendment | Initial Notification | |
| a) | Name | Bioventix plc | |
| b) | LEI | 213800225MHX7LZQY108 | |
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of 5 pence each GB00B4QVDF07 | |
| b) | Nature of the transaction | Issue of Options | |
| c) | Price(s) and volume(s) | Exercise Price(s) | Volume(s) |
| £17.75 £17.75 | 32,811 9,967 | ||
| d) | Aggregated information - Aggregated volume - Price | 42,778 £17.75 | |
| e) | Date of the transaction | 17 April 2026 | |
| f) | Place of the transaction | Outside a trading venue | |
| g) | Additional Information | N/A |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.